1 not yet recruiting. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Not yet recruiting 1 |
Follow Continue SoC ART: new trials by email Literature Review of Continue SoC ART trials Research Report on Continue SoC ART
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effects of Switch to Doravirine/Islatravir vs. Continued Antiretroviral Therapy on Biomarkers of Aging Among Virologically Suppressed People With HIV Switch from an ART regimen containing lamivudine (3TC) or emtricitabine (FTC) + tenofovir alafenamide (TAF) or tenofovir disoproxil fumarate (TDF) to DOR/ISL, Switch from an nucleoside reverse transcriptase inhibitor (NRTI)-sparing ART regimen containing greater than or equal to 2 drugs to DOR/ISL, Continue SoC ART - Epigenetic Aging | Phase 2 | Not yet recruiting | The University of Texas Health Science Center, Houston | 60 | 2026-10-30 | 2026-10-23 |
The University of Texas Health Science Center, Houston (1)
United States (1)